Skip to content
World City Press – Lifestyle
Author:
CONNECTA Therapeutics
CONNECTA Therapeutics Announces Financing to Advance Clinical Development of Fragile X Syndrome Program
September 10, 2026
CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome
June 10, 2026